• Explore /
  • Poster
  • / A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).

A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).

Abstract Poster

Authors

null

Simon Pacey

University of Cambridge, Cambridge, United Kingdom

Simon Pacey , Nimish Shah , Barry Davies , Ola Bratt , Anne Warren , Richard D. Baird , Vincent Gnanapragasam , Susan Ingle , Sara Stearn , Andrea Machin , Wendi Qian , Wanfeng Zhao , Elizabeth Harrington , Elisabeth Maria Oelmann , Mirela Hategan , Sanjeev Srinivas Kumar , Javier Garcia Corbacho

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer–Local-Regional Disease

Clinical Trial Registration Number

NCT02064608

Citation

J Clin Oncol 36, 2018 (suppl; abstr 5081)

DOI

10.1200/JCO.2018.36.15_suppl.5081

Abstract #

5081

Poster Bd #

308

Abstract Disclosures

Similar Posters

First Author: Simon Pacey

Poster

2023 ASCO Genitourinary Cancers Symposium

Evaluating p53 nuclear expression and prostate cancer progression in a predominantly African American cohort.

Evaluating p53 nuclear expression and prostate cancer progression in a predominantly African American cohort.

First Author: William Gesztes

First Author: Yao Zhu

First Author: Simon Pacey